drugset / Trial / NCT02477436

Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction

NCT02477436

Phase 2 Completed 159 enrolled Pusan National University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of Avanafil 50mg, 100mg, 200mg or placebo administered orally in patients with erectile dysfunction. In conclusions, Patients with erectile dysfunction (ED) were administered placebo, Avanafil 50mg, 100mg or 200mg 30 minutes before sexual intercourse for 8 weeks.

Timeline

Start
2008-02
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Avanafil Small molecule 50 mg Oral
Subject Avanafil Small molecule 100 mg Oral
Subject Avanafil Small molecule 200 mg Oral

Indications